Gary Douglas Myers

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial

Theodore W. Laetsch, Shannon L. Maude, Susana Rives et al. · Journal of Clinical Oncology · 2022 · 357 citations · Full text

Medicine, Hematology, Oncology +17

Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy

Vanessa A. Fabrizio, Jaap Jan Boelens, Audrey Mauguen et al. · Blood Advances · 2021 · 111 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia

Stephan A. Grupp, Shannon L. Maude, Susana Rives et al. · Blood · 2018 · 93 citations

Medicine, Hematology, Oncology +12

Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial

Theodore W. Laetsch, Gary Douglas Myers, André Baruchel et al. · The Lancet Oncology · 2019 · 89 citations · Full text

Medicine, Hematology, Oncology +14

Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Stephan A. Grupp, Theodore W. Laetsch, Jochen Buechner et al. · Blood · 2016 · 81 citations

Medicine, Oncology, Pediatrics +13